Mission & Vision

About SITC

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word “cure” a reality for cancer patients everywhere.

Currently, SITC has over 1,700 members representing 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer.

Through emphasis on high-caliber scientific meetings; dedication to education and outreach activities; focus on initiatives of major importance in the field; and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community.

Mission Statement

It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.

2016 Accomplishments Report

Core Values

  • Interaction/Integration: Facilitate the exchange of information and education among basic and translational researchers, clinicians, young investigators, societies and groups sharing the mission of SITC
  • Innovation: Challenge the thinking and seek the best research in the development of cancer immunotherapy
  • Translation: Facilitate the transfer of cancer immunology and immunotherapy research from the bench to the clinic and back
  • Leadership: Define what is new and important and effectively communicate it to all relevant stakeholders


  • Engage: Strengthen the society and create a more robust membership base by both attracting new members and retaining the active members through improvement of member benefits and cultivation of key constituency groups
  • Collaborate: Expand the society’s impact and influence by establishing relationships with key strategic partners
  • Learn: Provide education and training about the principles and practice of cancer immunotherapy to be widely recognized as the leading scientific voice in the field

Explore Our 2016 – 18 Strategic Plan